Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neuromedical Systems v. NeoPath

This article was originally published in The Gray Sheet

Executive Summary

United States federal district court in New York refuses to grant a preliminary injunction enjoining NeoPath from manufacturing and selling its AutoPap 300 QC system, Neuromedical Systems announces in a May 27 release. The court orders the parties to complete the discovery phase of the suit and return for a pretrial conference by the end of August, NSI adds. The company filed suit in July 1996, alleging that NeoPath "willfully misappropriated" NSI's Papnet automated cervical cytology reader technology and used the technology in the NeoPath AutoPap 300 QC ("The Gray Sheet" July 22, 1996, In Brief). NeoPath later filed suit in March 1997 in the U.S. District Court in Seattle claiming that NSI infringes three NeoPath patents ("The Gray Sheet" April 7, 1997, In Brief)

You may also be interested in...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts